<div class="headers"><div>Figure 4.Subgroup analysis (ITT population). Percent reduction over placebo in 28-day adjusted partial-onset seizure frequency during the treatment period in prior LEV and LEV-naive patients (A); ≥50% responder rate for partial-onset seizure frequency from baseline to the end of treatment period in prior LEV and LEV-naive patients (B); percent reduction over placebo in 28-day adjusted partial-onset seizure frequency during the treatment period according to reason for prior discontinuation of LEV* (C); ≥50% responder rate for partial-onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of LEV* (D); percent reduction over placebo in 28-day adjusted partial-onset seizure frequency during the treatment period according to number of prior AEDs (E); ≥50% responder rate for partial-onset seizure frequency from baseline to the end of treatment period according to number of prior AEDs (F). *Analysis by reason for prior discontinuation of LEV excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study. AEDs, antiepileptic drugs; BRV, brivaracetam; ITT, intention-to-treat; LEV, levetiracetam; PBO, placebo; POS, partial-onset seizure.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Figure 4.</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Subgroup analysis (ITT population). Percent reduction over placebo in 28-day adjusted partial-onset seizure frequency during the treatment period in prior LEV and LEV-naive patients (A); ≥50% responder rate for partial-onset seizure frequency from baseline to the end of treatment period in prior LEV and LEV-naive patients (B); percent reduction over placebo in 28-day adjusted partial-onset seizure frequency during the treatment period according to reason for prior discontinuation of LEV* (C); ≥50% responder rate for partial-onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of LEV* (D); percent reduction over placebo in 28-day adjusted partial-onset seizure frequency during the treatment period according to number of prior AEDs (E); ≥50% responder rate for partial-onset seizure frequency from baseline to the end of treatment period according to number of prior AEDs (F). *Analysis by reason for prior discontinuation of LEV excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study. AEDs, antiepileptic drugs; BRV, brivaracetam; ITT, intention-to-treat; LEV, levetiracetam; PBO, placebo; POS, partial-onset seizure.</p></td>
</tr>
</tbody>
</table>
